Last reviewed · How we verify
Analog Insulin
Analog insulin mimics endogenous insulin to regulate blood glucose by binding to insulin receptors and promoting glucose uptake in peripheral tissues.
Analog insulin mimics endogenous insulin to regulate blood glucose by binding to insulin receptors and promoting glucose uptake in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Analog Insulin |
|---|---|
| Also known as | Insulin Aspart and Insulin Glargine |
| Sponsor | National Institute of Neurosciences and Hospital, Dhaka |
| Drug class | Insulin analog |
| Target | Insulin receptor (INSR) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin analogs are synthetic modifications of human insulin designed to improve pharmacokinetic properties such as onset, peak, and duration of action. They bind to the insulin receptor on muscle, adipose, and liver cells to facilitate glucose transport and metabolism, thereby lowering blood glucose levels. Different analogs are engineered for rapid-acting, intermediate, or long-acting profiles to match physiological insulin secretion patterns.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (PHASE2)
- Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers (PHASE2, PHASE3)
- To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period (NA)
- Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump (PHASE3)
- Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State (PHASE1)
- Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Analog Insulin CI brief — competitive landscape report
- Analog Insulin updates RSS · CI watch RSS
- National Institute of Neurosciences and Hospital, Dhaka portfolio CI